2006
DOI: 10.1167/iovs.05-1373
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: CyS-PLGA-MS, displaying sustained intraocular release of CyS and showing advantages over CyS solution, may meet clinical needs more efficiently.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
15
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
3
2
1

Relationship

0
6

Authors

Journals

citations
Cited by 33 publications
(15 citation statements)
references
References 17 publications
0
15
0
Order By: Relevance
“…18 Polymeric systems have been used widely as implantable devices for controlled release of drugs in various organs. 19,20 In ophthalmic use, PLGA copolymers are used more commonly, for example, incorporating timolol for intraocular pressure control, 21 all-trans retinoic acid to reduce muscle adhesion in strabismus surgery, 22 cyclosporin for treatment of uveitis, 23 or 5-fluorouracil for antifibrotic effects. 24 In our study, we used PLC copolymers instead.…”
Section: Discussionmentioning
confidence: 99%
“…18 Polymeric systems have been used widely as implantable devices for controlled release of drugs in various organs. 19,20 In ophthalmic use, PLGA copolymers are used more commonly, for example, incorporating timolol for intraocular pressure control, 21 all-trans retinoic acid to reduce muscle adhesion in strabismus surgery, 22 cyclosporin for treatment of uveitis, 23 or 5-fluorouracil for antifibrotic effects. 24 In our study, we used PLC copolymers instead.…”
Section: Discussionmentioning
confidence: 99%
“…[84] Additionally, PLGA-based release systems have been studied as a promising candidate for the treatment of DED and uveitis, and they have been demonstrated a valid candidate for sustained release of therapeutics after a single administration through injection into ocular tissues. [85,86] In addition, a unique gelling, eye drop-like formulation has been recently reported that is able to comfortably retain the therapeutic drug in the lower fornix (topically) for a period of one month, while simultaneously releasing glaucoma medication over the period of time (without any injection into ocular tissues). [87] Although micro- and nanoparticles seem to possess significant potential as ocular drug delivery systems, limitations include encapsulation efficiency of drug (especially in smaller, nanoparticle formulations with high surface area), stability of the molecules during particle fabrication, control of particle size and drug release rate, and large-scale manufacturing of sterile preparations.…”
Section: Routes Of Ocular Administrationmentioning
confidence: 99%
“…[266,267] To overcome these limitations, microparticles containing cyclosporine have been under investigation as an alternative system for delivering the drug for a prolonged period of time, thus achieving a prolonged drug action with reduced side effects (Figure 12A). [86,266] In particular, it has been demonstrated that PLGA-based microparticles containing cyclosporine allow for a sustained concentration of the drug in the iris-ciliary body and choroid-retina of healthy rabbits for at least 65 days after injection (Figure 12B). [86] Moreover, the mean residence time of the drug loaded in the microparticles was ten times higher than cyclosporine solution.…”
Section: Ocular Diseasesmentioning
confidence: 99%
See 2 more Smart Citations